| Grant number: | 17/06146-8 |
| Support Opportunities: | Scholarships in Brazil - Post-Doctoral |
| Start date: | July 01, 2017 |
| End date: | August 31, 2022 |
| Field of knowledge: | Physical Sciences and Mathematics - Chemistry - Organic Chemistry |
| Agreement: | Coordination of Improvement of Higher Education Personnel (CAPES) |
| Principal Investigator: | Ronaldo Aloise Pilli |
| Grantee: | Carolyne Brustolin Braga |
| Host Institution: | Instituto de Química (IQ). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil |
| Associated research grant: | 13/07607-8 - OCRC - Obesity and Comorbidities Research Center, AP.CEPID |
| Associated scholarship(s): | 18/24020-4 - Polynorbornene-goniothalamin and polynorbornene-piplartine conjugates for cancer therapy, BE.EP.PD |
Abstract Biodegradable and biocompatible dendrimers and acetalated dextran (Ac-DEX) polymeric nanoparticles hold great promise as nanocarriers for the delivery of bioactivecompounds for anticancer therapy. The advantages of using these nanomaterials as drug delivery systems include enhanced water solubility, tumor-specific accumulation and improved antitumor efficacy, while reducing nonspecific toxicity, compared to the conventional small-molecule anticancer agents. Taking these aspects into account, together with the potent antitumor activity presented by goniothalamin (GTN), piplartine (PPT) and monastrol (MNT) against several tumorcell lines, the main goal of the current project is the development of new nanosystems for the selective delivery of each of these small molecules to diseased tissues. Specifically, this project aims to conjugate GTN, PPT and MNT via Click Chemistry to well-defined dendrimers, as well as to encapsulate these three bioactive compounds in Ac-DEX nanoparticles. Our strategy includes the synthesis of GTN, PPT and MNT analogues for conjugation to dendrimers in order to produce an efficient system for delivering of the corresponding active molecule to the tumor region. Also, the project will focus on obtaining enhanced formulations, through optimization, for example, of the loading and release properties of the delivery systems. The cytotoxicity of the new nanomaterials will be tested against several cell lines (tumor and healthy cells), and compared with the corresponding ones for the free drugs and empty nanocarriers, in order to define if these materials are valid candidates for the treatment of cancer. (AU) | |
| News published in Agência FAPESP Newsletter about the scholarship: | |
| More itemsLess items | |
| TITULO | |
| Articles published in other media outlets ( ): | |
| More itemsLess items | |
| VEICULO: TITULO (DATA) | |
| VEICULO: TITULO (DATA) | |